What disease does Pitobrutinib treat? What types of diseases is it mainly used to treat clinically?

Pirtobrutinib is a non-covalent (reversible) Bruton's tyrosine kinase (BTK) inhibitor, mainly used to treat B cell malignancies, especially in patients who are resistant to or failed to treat previous BTK inhibitors. It can effectively inhibit the BTK signaling pathway, thereby blocking the abnormal proliferation and survival of B cells, and is suitable for the treatment of various hematological malignancies.

In clinical practice, pitobrutinib is mainly used to treat mantle cell lymphoma (MCL), especially for ibrutinib (Ibrutinib) and acalabrutinib ( Patients who are resistant or intolerant to covalent BTK inhibitors such as Acalabrutinib or Zanubrutinib. In addition, it also shows good efficacy in chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) and other B cell-related hematological tumors, becoming a new treatment option.

Unlike traditional irreversibleBTK inhibitors, pitobrutinib can avoid the effects of C481S mutation ( span>BTK gene mutations), so it is still effective for patients who have previously received BTK inhibitors but developed resistance. This property makes it an important alternative for patients who have failed previous BTK inhibitor treatments, providing new hope for refractory or relapsed B cell lymphoma.

In terms of clinical application, pitobrutinib is usually administered in a once-daily oral dose and has a good safety profile. Common side effects include fatigue, diarrhea, thrombocytopenia, and mild infection. Due to its unique mechanism of action, researchers are also exploring its potential in other B cell malignancies (such as Waldenstrom's macroglobulinemia, marginal zone lymphoma, etc.) and in combination with other anti-cancer drugs to further expand its clinical application.

Reference materials:https://www.jaypirca.com/